BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Mexico Health Firm Genomma Shares Priced in IPO


6/18/2008 6:39:57 AM

MEXICO CITY, June 18 /PRNewswire-FirstCall/ -- Genomma Lab Internacional, S.A.B. de C.V. ("Genomma" or "the Company") today announced the pricing of its initial public offering. The offering consisted of 130,869,566 series B shares; 73.5% was placed with international investors and 26.5% was placed with Mexican investors.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080618/MXW007LOGO )

Excluding the overallotment option, 23.1% of the total offering size is being sold by Invex Trust No. 414 (existing shareholders) and ZN Mexico II, L.P. (one of the Nexxus family of Funds) on a pro rata basis. The shares are now listed on the Mexican Stock Exchange (ticker symbol "LAB"), and were distributed to institutional investors in the U.S. under Rule 144A and to investors outside the U.S. and elsewhere under Reg S.

The shares were offered at a price of Ps. 16 per Series B share, equivalent to US$1.54. At such price, the aggregate value of the offering is 2.4 billion pesos (2,408 millones de pesos) or approximately 233.6 million dollars, including overallotment options.

The Company's Chairman and Chief Executive Officer, Rodrigo Herrera, stated, "We are proud to be the first over-the-counter pharmaceutical and personal care products company that is traded on the Mexican Stock Exchange. This offering was successfully completed in very challenging market conditions and we thank everyone involved for their support.

"We plan to use these funds to support our rapid growth and we look forward to many years of continued expansion in the Mexican market."

Both the international offering and the local offering were well oversubscribed. Approximately 70% of the international offering was sold in the U.S. and 30% in Europe and the rest of the world. As a result of the Company's roadshow, the international book of demand was of exceptionally high quality and consisted of a combination of dedicated healthcare specialists and dedicated Latin American investors.

UBS Investment Bank was sole global coordinator of the international offering and joint bookrunner with Merrill Lynch. The lead underwriters of the Mexican offering were IXE Casa de Bolsa, S.A. de C.V., and Casa de Bolsa Santander, S.A. de C.V.

About Genomma

Genomma Lab Internacional, S.A.B. de C.V. is a leading over-the-counter pharmaceuticals and personal care products company in Mexico. Genomma trades on the Mexican Stock Exchange under the ticker symbol LAB.



CONTACT: Maria Barona, i-advize, +1-212-406-3691, mbarona@i-advize.com,
for Genomma



Read at Reuters
Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES